A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies

Trial Profile

A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Sirolimus (Primary) ; Vorinostat (Primary) ; Hydroxychloroquine
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
    • 12 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Oct 2016 Planned number of patients changed from 236 to 224.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top